top of page
Search
  • Writer's pictureVoisin Céline

Update on the umbrella clinical trial of the PIONeeR project as of October 30, 2023

Updated: Dec 7, 2023

Enrollment in the biomarker study is now completed (see news from January 5, 2023) but remains open in the PIONeeR Project’s umbrella clinical trial, which is evaluating the benefits of multiple treatment combinations in patients with different immune profiles, again with the unique goal of identifying the combination that has the best chance of improving patient survival and quality of life.

As of October 30, 2023, 152 patients have been screened for and 114 have entered the PIONeeR umbrella clinical trial (95% of expected inclusions).

NB: It is currently possible to directly include patients eligible for PIONeeR TRIAL after the same progression times as those previously included in PIONeeR BIOMARKERS:

  • From 6 weeks of treatment for 2nd and 3rd lines

  • After 12 weeks of treatment for 1st lines


Centre

Nombre de patients screenés

Nombre de patients inclus

CEPCM Marseille​

104

77

Oncopole Toulouse

21

17

CLC Léon Bérard, Lyon

27

20

Total

152

114


0 views0 comments

Comentarios


bottom of page